Difference between revisions of "Fujiwara Y, et al. Cancer Sci. (2019) cited as Ref 640 in DOI: 10.1038/s41392-020-0110-5 (Q9903)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: PubMed ID (P140): 30891877, #quickstatements; #temporary_batch_1590001671040)
(‎Created claim: Page(s) (P105): 1715-1723, #quickstatements; #temporary_batch_1590074839150)
 
(4 intermediate revisions by the same user not shown)
Property / Publication Date
 +
2019
Timestamp+2019-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2019 / rank
 +
Normal rank
Property / Published In Name String
 +
Cancer Sci.
Property / Published In Name String: Cancer Sci. / rank
 +
Normal rank
Property / Volume
 +
110
Property / Volume: 110 / rank
 +
Normal rank
Property / title
 +
Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors (English)
Property / title: Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors (English) / rank
 +
Normal rank
Property / Page(s)
 +
1715-1723
Property / Page(s): 1715-1723 / rank
 +
Normal rank

Latest revision as of 15:47, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Fujiwara Y, et al. Cancer Sci. (2019) cited as Ref 640 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Fujiwara Y
    0 references
    0 references
    2019
    0 references
    Cancer Sci.
    0 references
    110
    0 references
    Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors (English)
    0 references
    1715-1723
    0 references